Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson has maintained an Underweight rating on Adaptimmune Therapeutics (NASDAQ:ADAP) and lowered the price target from $2 to $1.
August 10, 2023 | 11:20 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Underweight rating on Adaptimmune Therapeutics and lowered the price target from $2 to $1, which could negatively impact the stock's price.
The lowered price target from Barclays indicates a bearish outlook for Adaptimmune Therapeutics. This could lead to a decrease in the stock's price as investors adjust their expectations based on this new target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100